EUCTR2015-005553-13-NL进行中（未招募）1 期
A PHASE 2, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EXPLORE THE PHARMACODYNAMICS, SAFETY AND EFFICACY OF TOPICAL OMIGANAN IN PATIENTS WITH EXTERNAL GENITAL WARTS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For enrollment of subjects the following criteria must be met:
- •1.Healthy male and female subjects = 18 years of age, with external genital warts. The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than genital warts following a detailed medical history and a complete physical examination including vital signs and 12-lead ECG. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •2.Clinically diagnosed and biopsy confirmed external genital warts. Subject has at least 3 external genital warts.
- •3.Willing to give written informed consent and willing and able to comply with the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Eligible subjects must meet none of the following exclusion criteria at screening:
- •1.Clinically significant abnormalities, as judged by the Investigator, in laboratory test results including haematology, blood chemistry panel, virology or urinalysis. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •2.Current clinically significant skin conditions in the anogenital area (e.g. atopic dermatitis, lichen sclerosus, lichen planus or psoriasis).
- •3.Pregnant, breast feeding or trying to conceive.
- •4.Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.
- •5.Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.
- •6.Use of active treatment (i.e. cryotherapy, laser therapy, topical medication and/or surgical treatments) for genital warts within 28 days prior to first study drug administration.
- •7.Immunosuppressed patients, having an immunodeficiency (primary or secondary, like HIV) or receiving immunosuppressive therapy (i.e. Transplant patients).
- •8.Males or Females who received a vaccination with Gardasil or Cervarix.
- •9.Any (medical) condition that would, in the opinion of the Investigator, potentially compromise the safety or compliance of the patient or may preclude the patient's successful completion of the clinical trial.
研究者
相似试验
已完成
2 期
A PHASE 2, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EXPLORE THE PHARMACODYNAMICS, SAFETY AND EFFICACY OF TOPICAL OMIGANAN IN PATIENTS WITH EXTERNAL GENITAL WARTS.voortplantingsstelsel- en borstaandoeningenvoortplantingsstelselinfecties en -ontstekingen, mannelijkCondylomata acuminataExternal genital warts10016417NL-OMON43535Cutanea Life Sciences24
进行中（未招募）
不适用
A study in volunteers with cutaneous warts to assess safety and efficacy of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide.Patients with at least two warts who are otherwise healthy subjectsMedDRA version: 17.1Level: LLTClassification code 10010115Term: Common wartsSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10035158Term: Plantar wartsSystem Organ Class: 100000004864EUCTR2014-003688-39-NLCutanea Life Sciences
已完成
2 期
A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Cutaneous WartsCutaneous warts10014982NL-OMON41194Centre for Human Drug Research80
进行中（未招募）
1 期
Digoxin / Furosemide topical therapy for genital warts and VIN lesions of immunocompromised and immunocompetent patientsEUCTR2016-000870-39-NLCutanea Life Sciences48
已完成
2 期
A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in HPV-induced genital lesions of immunocompromised and immunocompetent patients.genital warts / vulva dysplasia1004778910040899NL-OMON46258Cutanea Life Sciences48